Tetulomab

Tetulomab

Tetulomab is a drug being evaluated in Phase I/II clinical trials for the treatment of B-cell malignancies, specifically relapsed or refractory low-grade CD37-expressing non-Hodgkin lymphoma (NHL). It is administered as 177Lu-Tetraxetan-Tetulomab and has been shown in preclinical studies to successfully bind to lymphoma cell lines and biopsies from NHL patients and tumors in mice models.From: Chemistry and Pharmacology of Anticancer Drugs [2021], Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies [2018]

Antibody-Based Therapies

View Chapter

Purchase Book

Published in David E. Thurston, Ilona Pysz, Chemistry and Pharmacology of Anticancer Drugs, 2021

David E. Thurston, Ilona Pysz

177Lu-Tetraxetan-Tetulomab (BetalutinTM) is based on a murine monoclonal antibody discovered at the Norwegian Radium Hospital and is now being developed by Nordic Nanovector. It is targeted to the CD37 glycoprotein found on the surface of mature malignant and nonmalignant human B cells, and is being used as a tumor-targeting carrier for both radioactive and cytotoxic payloads for the treatment of hematological cancers. BetalutinTM itself consists of the CD37-targeting monoclonal antibody tetulomab conjugated to the short-lived beta-emitting Lutetium radionuclide 177Lu (Figure 7.41). Structure of the Antibody-Radionuclide Conjugate 177Lu-Tetraxetan-Tetulomab (Betalutin™) (Figure reprinted with permission from Nordic Nanovector ©).

Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies

View Article

Journal Information

Published in Expert Opinion on Investigational Drugs, 2018

Magdalena Witkowska, Piotr Smolewski, Tadeusz Robak

According to the preclinical studies mentioned above, 177Lu-tetulomab successfully binds to lymphoma cell lines and biopsies from NHL patients and tumors in mice models. It indicates that CD37 can be an excellent target for RIT and this should be investigated in future clinical studies.

Explore chapters and articles related to this topic

Antibody-Based Therapies

Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies